Pharming Group (NASDAQ:PHAR) Shares Gap Down - What's Next?

Key Points

• Pharming Group's stock gapped down from $14.67 to $14.22 before opening, with the latest price at $14.45 and a trading volume of 757 shares.
• Wall Street analysts maintain an average rating of "Hold" on Pharming Group, with a target price of $30.00, although Zacks downgraded it from "strong-buy" to "hold".
• The company reported a Q2 earnings per share of $0.06, exceeding expectations, and had a revenue of $93.20 million, significantly higher than the $70.36 million forecasted by analysts.

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $14.67, but opened at $14.22. Pharming Group shares last traded at $14.45, with a volume of 757 shares.

Wall Street Analysts Forecast Growth

PHAR has been the subject of a number of research analyst reports. Weiss Ratings reissued a "sell (d+)" rating on shares of Pharming Group in a report on Wednesday. Zacks Research cut Pharming Group from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 30th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Pharming Group has an average rating of "Hold" and an average target price of $30.00.

Pharming Group Stock Performance

The company has a debt-to-equity ratio of 0.38, a current ratio of 2.79 and a quick ratio of 2.07. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -113.38 and a beta of 0.04. The firm has a fifty day moving average of $13.63 and a 200 day moving average of $11.09.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.16. The company had revenue of $93.20 million during the quarter, compared to analyst estimates of $70.36 million. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%. Pharming Group has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,147 shares of the company's stock after buying an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.08% of Pharming Group worth $557,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.